Nvidia-backed Iambic Therapeutics will begin trading Thursday after pricing its $150 million initial public offering Wednesday night.
The cancer-focused biotech sold …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.